• It's like a smaller, vertically integrated company combining the diverse health product manufacturing of Perrigo (known for OTCs and generics) with the robust distribution capabilities of a Cardinal Health.
• Imagine a pharmacy chain's private label brand (like CVS Health's store brand) but expanded to include branded and generic pharmaceuticals, medical devices, and with its own extensive distribution and e-commerce network.

• Branded Pharmaceuticals: Proprietary drugs marketed under specific brand names.
• Generic Pharmaceuticals: Cost-effective versions of existing drugs once their patents expire.
• Nutraceuticals: Products derived from food sources that are believed to provide extra health benefits in addition to their basic nutritional value.
• Over-the-Counter (OTC) Medications: Drugs that can be purchased without a prescription.
• Health Care Products: A general category encompassing various items designed for maintaining or improving health.
• Baby Products: Specialized goods designed for the care and needs of infants and young children.
• Medical Devices: Instruments, apparatus, implants, in vitro reagents, or similar articles used to diagnose, prevent, monitor, treat, or alleviate disease.

• Wholesale pharmaceutical distributors
• Independent retail pharmacies

Grigorios Siokas, Chairman & Chief Executive Officer

Mr. Grigorios Siokas has served as the Chairman and Chief Executive Officer of Cosmos Health Inc. since February 2016. He brings over 15 years of experience in the pharmaceutical industry. Prior to his current role, he was the CEO and Operations Manager of SkyPharm S.A., a wholly-owned subsidiary of Cosmos Health, since 2014. Mr. Siokas has also held ownership and operating roles in European pharmaceutical distribution and was a major shareholder in several pharmaceutical companies before 2014, including Ippokratis Pharmaceuticals, Thrakis Pharmaceuticals, Thessalias Pharmaceuticals, and ZED Pharma SA. He briefly served as acting CFO for Cosmos Health until November 2020. Mr. Siokas holds a Bachelor's degree in Geology from Aristotle University of Thessaloniki and a Master's degree in management and finance from the University of Stuttgart and the University of Tuebingen. He has consistently demonstrated his commitment to the company by increasing his ownership through various stock purchases and debt exchange agreements, having invested over $18 million since Cosmos Health's inception.

Georgios Terzis, Chief Financial Officer

Mr. Georgios Terzis is the Chief Financial Officer and Principal Accounting Officer of Cosmos Health Inc. In this role, he is responsible for managing the company's financial operations and capital structure. Mr. Terzis has also increased his stake in the company through share purchases, indicating his confidence in Cosmos Health's future.

Nikolaos Bardakis, Chief Operating Officer

Mr. Nikolaos Bardakis serves as the Chief Operating Officer for Cosmos Health Inc. He is responsible for overseeing the company's day-to-day business operations and ensuring operational efficiency.

Dimitris Moraitis, Vice President of Strategy & Operations

Mr. Dimitris Moraitis was appointed as the Vice President of Strategy & Operations for Cosmos Health Inc. in February 2025. He brings over 25 years of extensive experience in strategic planning, operations, and business development within the pharmaceutical sector. Throughout his career, Mr. Moraitis has held key leadership positions at prominent pharmaceutical companies such as DEMO, MENARINI, the VIANEX Group, and TIKUN OLAM Europe. He has also served as a leader and board member for several well-known pharmaceutical associations.

The key risks to Cosmos Health's business (NASDAQ: COSM) include its ongoing financial instability and lack of profitability, significant regulatory and compliance challenges particularly within its nutraceutical segment, and substantial exposure to the volatility of digital assets.

The most significant risk to Cosmos Health is its **financial instability and persistent lack of profitability**. The company has consistently reported negative operating margins and a negative return on invested capital (ROIC), indicating that it is losing money. Cosmos Health has an accumulated deficit and a weak balance sheet, facing large current liabilities and often requiring additional financing to meet its obligations, leading to "going concern" disclosures. Its financial strength has been rated as poor, with a negative Altman Z-Score, which places the company in the distress zone and suggests a potential risk of bankruptcy within the next two years. The stock has also experienced high volatility and a significant decline in share price.

Secondly, Cosmos Health faces considerable **regulatory and compliance risks**, particularly concerning its nutraceutical business, which is a primary financial driver. While its pharmaceutical operations are subject to stringent regulations from bodies like the FDA, the nutraceutical industry is less regulated, which can lead to issues with product claims, safety, and efficacy. Failure to comply with these regulations can result in severe legal and financial penalties, including product recalls and liability. Additionally, a specific "drug preclusion provision" under FDA rules for nutraceuticals can create coverage gaps for certain products.

Lastly, Cosmos Health's **exposure to cryptocurrency volatility** presents a notable risk. The company has a significant digital financing facility and has invested in digital assets, including Ethereum and Bitcoin. This strategy means the company's financial health and balance sheet are directly influenced by the highly volatile cryptocurrency market, which could lead to unpredictable and substantial swings in its financial position.

The increasing market penetration and potential vertical integration of large technology and e-commerce giants into the pharmaceutical and healthcare product distribution space. Companies like Amazon have already launched online pharmacies and are continually expanding their logistics and direct-to-consumer capabilities. This trend threatens traditional pharmaceutical distribution channels, including those relied upon by Cosmos Health, and could put significant pressure on its customer base of independent retail pharmacies and wholesale distributors by offering more streamlined and potentially lower-cost alternatives. This parallels the disruption seen in other industries where tech companies have leveraged their scale and efficiency to displace established intermediaries.

Cosmos Health (symbol: COSM) operates in several key addressable markets primarily within Europe, encompassing pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, and medical devices.

Addressable Markets for Cosmos Health's Main Products and Services in Europe:

• Generic Pharmaceuticals: The European generic pharmaceuticals market was valued at approximately USD 136.17 billion in 2025 and is projected to reach around USD 235.82 billion by 2033. Within this, the Europe branded generics market was valued at USD 39.15 billion in 2023 and is projected to reach approximately USD 70.84 billion by 2033.
• Branded Pharmaceuticals: The broader European pharmaceutical market, which includes branded pharmaceuticals, was estimated at USD 488.05 billion in 2024 and is projected to grow to USD 820.05 billion by 2034. The branded segment held a dominant revenue share of 66.49% in this market in 2024.
• Nutraceuticals: The Europe nutraceuticals market size was calculated to be USD 143.74 billion in 2025 and is anticipated to be worth USD 286.63 billion by 2034.
• Over-the-Counter (OTC) Medications / OTC Health Products: The Europe OTC Health Product Market was valued at USD 125.4 billion in 2025 and is projected to reach USD 209.8 billion by 2032.
• Medical Devices: The European medical devices market was valued at approximately USD 193.9 billion in 2024 and is projected to hit USD 305.01 billion by 2033.

Expected Drivers of Future Revenue Growth for Cosmos Health (COSM)

Over the next 2-3 years, Cosmos Health (NASDAQ: COSM) anticipates several key drivers to fuel its revenue growth:

1. Expansion into Higher-Margin Products and Services: Cosmos Health is strategically shifting its focus towards higher-margin pharmaceutical products, branded nutraceuticals, and technology-enabled services. This includes the continued global expansion of its flagship nutraceutical brand, Sky Premium Life, which added over 60 new formulations in 2025, bringing its total to over 150 products.
2. Growth of Distribution Network and Customer Base: The company's pharmaceutical distribution subsidiary, Cosmofarm, is expanding its reach. In 2025, it added nearly 100 new pharmacy customers, increasing its active customer base by approximately 20%, and anticipates similar or higher growth rates in 2026. This expansion is further bolstered by a disciplined acquisition strategy, such as the recently announced Letter of Intent to acquire a pharmacy distribution network in Greece, which is expected to add approximately $11.5 million in annual gross revenue.
3. Investments in Automation and Logistics Infrastructure: Cosmos Health is enhancing its operational efficiency and capacity through significant investments in automation. Cosmofarm's multi-year, multi-million dollar investments in advanced robotic systems, including ROWA and A-frame technologies, are projected to increase processing capacity, improve accuracy, and support an incremental annual revenue potential of approximately $40 million.
4. Launch of New Pharmaceutical Products and R&D Advancements: The company is actively developing and commercializing new products. Its research and development efforts include advancing an obesity treatment, CCX0722, towards clinical trials with a potential launch in 2026, and expanding its pipeline in therapeutic areas such as autoimmune diseases, neurology, oncology, and allergies. Cosmos Health is also focused on developing novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative over-the-counter products.
5. U.S. Market Expansion and Domestic Manufacturing: Cosmos Health is strategically entering the U.S. market and establishing domestic manufacturing capabilities through an agreement with DolCas Biotech. This move is designed to reduce exposure to tariff volatility, strengthen supply-chain resilience, and produce products where they are sold, representing a structural shift in its market approach.

Share Issuance

• Cosmos Health's CEO, Grigorios Siokas, acquired approximately $339,999 worth of shares in January and February 2026 through debt exchange agreements, where the company issued shares to settle its debt.
• The company plans to implement a reverse stock split if necessary to regain compliance with Nasdaq's minimum bid price requirement by mid-2026.
• Cosmos Health had 35 million shares outstanding in Q3 2025, marking a 15.6% increase from the prior quarter.

Inbound Investments

• In August 2025, Cosmos Health secured a financing facility of up to $300 million from a U.S. institutional investor through senior secured convertible promissory notes.
• Approximately 72.5% of the net proceeds from this financing facility are allocated to building a digital treasury reserve, including cryptocurrencies like Ethereum, Bitcoin, and Solana, with the remainder supporting working capital and growth initiatives.
• The company partnered with Prime Ledger LLC to manage this $300 million treasury facility and to digitally transform its financial operations.

Outbound Investments

• Cosmos Health acquired ZipDoctor, a U.S. telehealth subscription business, in 2023, and Cloudscreen, an AI-enabled drug-repurposing and R&D platform, in early 2024.
• The company has built a digital treasury reserve, with total digital asset investments exceeding $3.1 million as of March 2026, through purchases of Ethereum and Bitcoin.
• In March 2026, Cosmos Health entered into a Letter of Intent to acquire an extensive pharmacy distribution network in Greece, which is expected to generate approximately $11.5 million in annual gross revenue.

Capital Expenditures

• An investment program of approximately $1 million is currently underway at Cosmofarm, its Greek subsidiary, to expand robotic capacity and throughput for its logistics platform as of January 2026.
• Cana Laboratories completed Phase I upgrades to its 54,000-square-foot manufacturing facility in Athens.
• Cosmofarm's 29,000-square-foot property in Athens is undergoing upgrades including modernized office space, expanded distribution areas, and enhanced temperature-controlled storage.